Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
Diabetes, Obesity & Metabolism|February 24, 2012
Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled studyThomas Haak, T Meinicke, R Jones, et al.
Diabetes, Obesity & Metabolism|June 5, 2015
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trialJ Rosenstock, A Jelaska, C Zeller, et al.
International Journal of Clinical Practice|October 15, 2013
Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension studyT Haak, T Meinicke, R Jones, et al.
Diabetes, Obesity & Metabolism|April 2, 2015
Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16-week, randomized, placebo-controlled trialS Ross, C Thamer, J Cescutti, et al.
Gut|June 30, 2005
Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humansJ Schirra, M Nicolaus, R Roggel, et al.
Diabetes, Obesity & Metabolism|May 29, 2014
Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 yearsG Schernthaner, A H Barnett, S Patel, et al.
Diabetes, Obesity & Metabolism|April 10, 2013
Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetesN Inagaki, H Watada, M Murai, et al.
European Journal of Drug Metabolism and Pharmacokinetics|February 23, 2011
Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteersC Friedrich, A Ring, T Brand, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|May 15, 2014
Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind studyM Bajaj, R Gilman, S Patel, et al.
Diabetes, Obesity & Metabolism|May 14, 2014
The dipeptidyl peptidase-4 inhibitor linagliptin lowers postprandial glucose and improves measures of β-cell function in type 2 diabetesT Heise, M Larbig, S Patel, et al.
Pageof 5